Barriers, Drivers, and Outcomes in Transitioning Patients With Inflammatory Bowel Disease From Intravenous to Subcutaneous Infliximab
Understanding patients' attitudes toward transition is essential to design a service that meets their needs. Services must be adequately resourced in order to ensure that patients treated with subcutaneous biologics continue to have ready access to high-quality care.
Authors
- Eoin Slattery (ORCID: https://orcid.org/0000-0003-1543-1586)
- Linda Duane
- John Campion (ORCID: https://orcid.org/0000-0002-8722-6293)
- Emma McCormick
- Laurence John Egan (ORCID: https://orcid.org/0000-0002-0142-6340)
- Kyle T. Finn (ORCID: https://orcid.org/0000-0003-3119-9510)
- Renan Cunha-Melo Jose
- Mary Hussey
- Áine Keogh
Institutions
- Ollscoil na Gaillimhe – University of Galway (IE)
- University Hospital Galway (IE)
- COPE Galway (IE)
Publication Details
- Journal
- Crohn s & Colitis 360
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1093/crocol/otaf008
- Citations
- 1
- Primary Topic
- Adolescent and Pediatric Healthcare
- Type
- article
- Field-Weighted Citation Impact
- 3.12